Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...
– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries – – Topline Results Suggest a Significant...
- On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 - - $94.2 Million in Cash...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of...
- Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women - - Among HPA-1a Negative Pregnant Women...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.